Chardan Capital Reiterates “Buy” Rating for uniQure (NASDAQ:QURE)

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reiterated by equities researchers at Chardan Capital in a research note issued on Friday,Benzinga reports. They presently have a $38.00 target price on the biotechnology company’s stock. Chardan Capital’s target price suggests a potential upside of 160.99% from the company’s previous close.

Other analysts also recently issued reports about the company. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, May 24th. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of uniQure in a report on Thursday. Guggenheim reissued a “buy” rating and set a $28.00 price objective on shares of uniQure in a research note on Monday, May 12th. Cantor Fitzgerald raised shares of uniQure to a “strong-buy” rating in a research note on Monday, May 19th. Finally, Wells Fargo & Company reduced their price objective on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $37.82.

uniQure Price Performance

Shares of QURE opened at $14.56 on Friday. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The stock’s 50 day moving average is $12.53 and its two-hundred day moving average is $12.91. The firm has a market capitalization of $797.54 million, a PE ratio of -2.94 and a beta of 0.10. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last issued its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.25. The company had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Research analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the transaction, the chief executive officer now directly owns 651,454 shares in the company, valued at $6,703,461.66. This represents a 4.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Christian Klemt sold 10,438 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $107,407.02. Following the sale, the chief financial officer now owns 217,730 shares in the company, valued at $2,240,441.70. This trade represents a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,129 shares of company stock worth $412,927 over the last 90 days. Corporate insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 969 shares during the last quarter. Tudor Investment Corp ET AL grew its stake in shares of uniQure by 5.9% during the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock worth $438,000 after buying an additional 1,371 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of uniQure by 13.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after buying an additional 1,503 shares during the last quarter. Northern Trust Corp grew its stake in shares of uniQure by 2.1% during the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock worth $1,688,000 after buying an additional 1,923 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of uniQure by 6.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock worth $1,253,000 after buying an additional 3,996 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.